Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
Conditions
Interventions
VG2025
Nivolumab Injection [Opdivo]
Locations
2
United States
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
MD Anderson
Houston, Texas, United States
Start Date
November 9, 2022
Primary Completion Date
December 31, 2024
Completion Date
December 31, 2025
Last Updated
August 9, 2024
NCT05720117
NCT06898450
NCT06658951
NCT06625775
NCT05223608
NCT05719558
Lead Sponsor
Virogin Biotech Canada Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions